Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 3 of 3 for “"HRD phenotype"”.

  1. Characterisation of the tumour microenvironment in homologous recombination-deficient prostate cancer

    … Here, two novel mouse models of HR-deficient (HRD) prostate cancer were developed by abrogating expression of <em>Palb2 </em>in MyC-CaP (Hi-<em>Myc</em>) and DVL3 (<em>Pten</em><sup>-/-</sup>, <em>Trp53</em><sup>-/-</sup>) cells. Functional validation of CRISPR Palb2 (cr<em>Palb2</em>) cells …

    oxford Restricted access

  2. Characterization of allele-specific 5-methylcytosine in cancer and quantification of 8-oxoguanine using nanopore sequencing

    … relevant homologous recombination deficiency (HRD) phenotype. Breast and ovarian cancers with aberrant methylation were found to be enriched in somatic alterations in gene regulatory regions. A subset of HRD cases, were found to have promoter indels which may be acting as reversion mutations to …

    ubc Repository record for Characterization of allele-specific 5-methylcytosine in cancer and quantification of 8-oxoguanine using nanopore sequencing (opens in a new tab) Download PDF for Characterization of allele-specific 5-methylcytosine in cancer and quantification of 8-oxoguanine using nanopore sequencing (opens in a new tab)

  3. Structural variants of BRCA1/2 as a novel biomarker of homologous recombination deficiency

    Homologous recombination deficiency (HRD) represents a cancer vulnerability that has been successfully exploited through the use of PARP inhibitors by synthetic lethality. In high grade serous ovarian cancer (HGSOC), PARP inhibitors, such as olaparib, have revolutionised treatments outcomes for …

    edinburgh Repository record for Structural variants of BRCA1/2 as a novel biomarker of homologous recombination deficiency (opens in a new tab) Restricted access